Immune-related adverse events of biological immunotherapies used in COVID-19
The use of biological immunotherapeutic drugs is one of the options currently being evaluated and employed to manage COVID-19, specifically monoclonal antibodies, which have shown benefit by regulating the excessive immune response seen in patients with severe infection, known as a cytokine storm. T...
Saved in:
Main Authors: | Daniela Baracaldo-Santamaría (Author), Giovanna María Barros-Arias (Author), Felipe Hernández-Guerrero (Author), Alejandra De- (Author), Carlos-Alberto Ca (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
by: Liting Sun, et al.
Published: (2023) -
Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
by: Sayuri Yoshikawa, et al.
Published: (2022) -
Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019) -
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation
by: Lilia Bardoscia, et al.
Published: (2021) -
Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
by: Xiujing He, et al.
Published: (2021)